More MS news articles for April 2004

American Academy of Neurology 56th Annual Meeting
Schering Reports Favorable Early Results With High-Dose Betaferon for MS

http://www.medscape.com/viewarticle/474863

April 30, 2004
Reuters

German drugmaker Schering AG on Friday unveiled upbeat early results of phrase III tests in its "Beyond" trial, one of the biggest multiple sclerosis (MS) studies ever.

Initial results from the trial showed that a higher dose of its key multiple sclerosis drug Betaferon may have a positive effect on relapsing-remitting MS patients, compared to the standard dose.

"These first data support our conviction that a higher dose of Betaferon could exert even greater therapeutic benefits for MS patients than known from any other drug on the market," Joachim-Friedrich Kapp, head of specialised therapeutics at Schering, said in a statement.

The Beyond program is a continuing multinational, phase III trial and involves more than 2,000 patients. The data, the first efficacy outcomes from the study, were presented at a conference in San Francisco.